Bioinformatics-Driven mRNA-Based Vaccine Design for Controlling Tinea Cruris Induced by Trichophyton rubrumArticle Published on 2024-07-252024-09-05 Journal: Pharmaceutics [Category] update2024, [키워드] bioinformatics mRNA-based vaccine tinea cruris Trichophyton rubrum [DOI] 10.3390/pharmaceutics16080983 PMC 바로가기 [Article Type] Article
An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerationsArticle Published on 2023-02-272024-09-05 Journal: International immunopharmacology [Category] update2024, [키워드] Horizontal gene transfer (HGT) immunization mRNA-based vaccine SARS-CoV-2 vaccination [DOI] 10.1016/j.intimp.2023.109934 PMC 바로가기 [Article Type] Article
Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccinesArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Ad26.COV2.S Ad26.COV2.S vaccine antibody B.1.1.529 B.1.1.7 B.1.351 B.1.617.2 Beta BNT162b2 BNT162b2 vaccine booster center contributed Control COVID-19 Delta dose Effectiveness elicited faster FIVE Gamma immunization moderate mRNA-1273 mRNA-based vaccine Mutation Neutralizing Neutralizing antibodies neutralizing antibody omicron P.1 postvaccination prevention Protein pseudovirus receiving recipient recommendation robust SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 variant subject Support vaccination Vaccine vaccine efficacy variants of concern variants of concern (VOCs) VoC VOCs wild type [DOI] 10.1002/jmv.28032 PMC 바로가기
mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concernmRNA 기반 백신은 우려되는 다양한 SARS-CoV-2 변이체에 대한 광범위한 보호를 제공합니다.Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Beta Clinical use COVID-19 COVID-19 mRNA vaccine COVID-19 mRNA vaccines cross-reactive Delta described exhibited Heterologous homologous immunogenicity indicated Messenger RNA mRNA mRNA vaccine mRNA-based vaccine mRNA-based vaccines nCoV neutralization omicron overcome pandemic of COVID-19 SARS-CoV-2 variant SARS-CoV-2 variants Vaccine variants [DOI] 10.1080/22221751.2022.2081616 PMC 바로가기 [Article Type] Article
Antibody response and intra-host viral evolution after plasma therapy in COVID-19 patients pre-exposed or not to B-cell-depleting agentsArticle Published on 2022-11-012022-11-15 Journal: British Journal of Haematology [Category] SARS, 진단, [키워드] anti-CD20 anti-CD20 therapy Anti-spike anti-Spike IgG antibody antibody kinetics B-cell clinical care clinical status clinical symptom Complete contribute convalescent convalescent plasma COVID-19 patient Decline donors eligible evaluated Follow-up hospitalized COVID-19 patients humoral Humoral immunity IgG Immune escape Immunocompromised Immunocompromised patients Immunoglobulin impair lymphopenia majority management mRNA-based vaccine mRNA-based vaccine plasma mutation rate Patient patients treated plasma receiving SARS-CoV-2 SARS-CoV-2 viral load SARS-CoV-2-specific antibodies severity spike mutations survival therapy titre viral control viral evolution virus clearance WHO whole-genome sequencing World Health Organization [DOI] 10.1111/bjh.18450 PMC 바로가기
mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulationsArticle Published on 2022-10-062022-11-15 Journal: Vaccine [Category] 진단, 치료기술, [키워드] administration Adverse reactions antibodies antibody Antibody Response association BNT162b2 component coronavirus disease correlated COVID-19 detectable drug elicited ELISA enzyme glycerol glycol immune response immunosorbent increase in induce Influenza virus injection Interaction Lipid Lipid nanoparticle low molecular weight Messenger RNA mRNA mRNA vaccine mRNA-1273 mRNA-1273 vaccine mRNA-based vaccine participant polyethylene Polyethylene glycol Prevent reactive reactivity SARS-CoV-2 selected sera serum severe allergic reactions vaccination Vaccine vaccine-associated side effect vaccinee [DOI] 10.1016/j.vaccine.2022.08.024 PMC 바로가기
The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patientsArticle Published on 2022-09-292022-11-15 Journal: Frontiers in Immunology [Category] SARS, 진단, 치료기술, [키워드] antibodies antibody Antibody Response B cell B cell response B cells B-cell B-cell response binding activity Blood booster dose Cell collected COVID-19 dose dose administration elicited ENhance Frequency healthy controls humoral immune response immune responsiveness Immunosuppressive treatment in vitro increase Interaction JAK inhibitor memory B memory B-cell Moderna mononuclear cell mRNA mRNA SARS-CoV-2 vaccination mRNA vaccine mRNA-1273 mRNA-based vaccine myelofibrosis Patient patients Peripheral blood positive remained responders ruxolitinib SARS-CoV-2 SARS-CoV-2 BNT162b2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine second vaccination significant increase significantly increased Spike-specific antibody spike-specific IgG subject subjects tested the SARS-CoV-2 therapy third booster dose. treated untreated patients vaccination vaccine dose Vaccines was measured while [DOI] 10.3389/fimmu.2022.1017863 PMC 바로가기
Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccinationArticle Published on 2022-09-012022-11-15 Journal: RMD Open [Category] SARS, 진단, [키워드] activated Activation antibody Autoimmune Autoimmune diseases Cellular immune response cellular response Combination correlated COVID-19 COVID-19 vaccination csDMARD cytokine cytokine profile drug drugs evaluated female first vaccination Frequency Heterologous highest humoral IgG immunosuppressive immunosuppressive therapy Inflammatory inhibitor investigated majority marker median age medications methotrexate monotherapy mRNA-based vaccine MTX Neutralising Antibodies neutralising antibody no difference not significant outcome Patient psoriatic arthritis quantification receiving rheumatic disease rheumatoid arthritis SARS-CoV-2 second vaccination Seroconversion spike-protein spondyloarthritis T-cell T-cell immunity T-lymphocyte T-lymphocyte subsets Therapies therapy titre treated vaccination [DOI] 10.1136/rmdopen-2022-002293 PMC 바로가기
Associations of Guillain-Barré syndrome with coronavirus disease 2019 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance databaseArticle Published on 2022-09-012022-11-16 Journal: Journal of the peripheral nervous system : JPNS [Category] 변종, [키워드] acute respiratory syndrome Administered Analysis association AstraZeneca Cambridge cause ChAdOx1 nCoV-19 coronavirus coronavirus disease COVID-19 COVID-19 vaccination COVID-19 vaccine database demonstrated Encephalitis Epidemiological study greater Guillain-barrè syndrome Guillain-Barré syndrome variants heterogeneity higher risk Influenza influenza vaccine influenza vaccines information median time Moderna mRNA-based vaccine Occurrence Odds ratio Pfizer reported risk SARS-CoV-2 syndrome the WHO vaccination Vaccines variant World Health Organization [DOI] 10.1111/jns.12507 PMC 바로가기
Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant델타 변종에 대한 코로나바이러스 질병 2019(COVID-19) 백신의 비교 효과Comparative Study Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Ad26 Ad26.COV2.S Ad26.COV2.S vaccine Against Analysis approved BNT162b2 Comparative comparative effectiveness contributed coronavirus coronavirus disease Coronavirus disease 2019 covariate COVID-19 COVID-19 hospitalization COVID-19 vaccine COVID-19 vaccines Cox model declined Delta delta variant effective Effectiveness Efficacy hazard ratio Healthcare system Hospitalization Immunity impacted Infection IPW Kaplan-Meier lack large cohort lower risk Medicine Moderna mRNA mRNA-1273 mRNA-1273 vaccine mRNA-based vaccine mRNA-based vaccines Patient Pfizer-BioNTech recipient recipients risk SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus significantly vaccination Vaccine variant waning immunity [DOI] 10.1093/cid/ciac106 PMC 바로가기 [Article Type] Comparative Study